Konstantinos Tsapakidis | Immunotherapy | Excellence in Research

Konstantinos Tsapakidis | Immunotherapy | Excellence in Research

Assist. Prof. Dr. Konstantinos Tsapakidis, University Hospital Of Larissa, Greece

Assist. Prof. Dr. Konstantinos Tsapakidis πŸŽ“πŸ‘¨β€βš•οΈ is an esteemed Medical Oncologist at the University of Thessaly, Greece. With a Ph.D. focused on prostate cancer research, he holds European Certification in Medical Oncology πŸ…. Since 2018, he has been actively involved in clinical oncology, teaching postgraduate courses on cancer, diet, and immunotherapy 🍽️🧬. Dr. Tsapakidis has authored numerous impactful publications πŸ“š, contributing significantly to cancer diagnostics and treatment. Passionate about education, he trains residents and nurses, advancing oncology knowledge. His expertise includes systemic antineoplastic therapies and immune-oncology 🌟.

Publication Profile

Orcid

Education

Assist. Prof. Dr. Konstantinos Tsapakidis πŸŽ“ is a dedicated Medical Oncologist with an impressive educational background. He earned his Biology degree from Aristotelian University of Thessaloniki 🧬 (1998–2002) and completed his Medicine degree at the University of Thessaly πŸ₯ (2003–2007). Dr. Tsapakidis achieved his Ph.D. with excellence (2005–2012), researching prostate cancer’s cell-cycle and apoptosis mechanisms πŸ”¬. He specialized in Medical Oncology in 2017 🎯 and obtained the prestigious European Certification in Medical Oncology in 2018 πŸ…. He also enhanced his expertise through an Immune-Oncology e-learning program at the University of Piraeus in 2017–2018 πŸ’».

Experience

Assist. Prof. Dr. Konstantinos Tsapakidis πŸ’Ό has extensive medical oncology experience. Since February 2025, he serves as Assistant Professor at the University of Thessaly πŸŽ“. From 2018 to 2025, he worked as Consultant in Medical Oncology at University Hospital of Larissa πŸ₯. Previously, he was a University Scholar and Fellow Consultant there (2017–2018) πŸ‘¨β€βš•οΈ. He completed his residency in Medical Oncology (2014–2017) and earlier trained in Internal Medicine and Hematology at Larissa hospitals 🩺. Between 2008–2009, he was a Scientific Associate in Medical Oncology, laying a strong foundation for his clinical career πŸ”¬.

Research Focus

Assist. Prof. Dr. Konstantinos Tsapakidis’s research focus lies primarily in Medical Oncology with a strong emphasis on cancer diagnosis, treatment, and immunotherapy. 🧬🩺 His work explores various cancer types including lung cancer, breast cancer, sarcomas, and rare cancers, investigating immunotherapy responses, molecular diagnostics, and tumor behavior. πŸ”¬πŸ’‰ He is particularly involved in studying biomarkers like PD-1/PD-L1, immune cell profiling, and novel therapeutic approaches to improve patient outcomes. πŸ§ͺβš•οΈ His research also covers cancer-associated complications like thrombosis and metastatic disease. Overall, his contributions advance personalized oncology care and innovative cancer treatment strategies.

Publication Top Notes

Pseudomyxoma Peritonei: A Challenging Clinical Diagnosis. Case Report and Review of the Literature

The Impact of Expert Pathology Review and Molecular Diagnostics on the Management of Sarcoma Patients: A Prospective Study of the Hellenic Group of Sarcomas and Rare Cancers

Pre-Existing Immunity Predicts Response to First-Line Immunotherapy in Non-Small Cell Lung Cancer Patients

ES-SCLC Patients with PD-L1+ CTCs and High Percentages of CD8+PD-1+T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment

Combinatorial analysis of CD4<SUP>+</SUP>Tregs and CD8<SUP>+</SUP>Teff to predict response to ICI in patients with ES-SCLC

Metachronous Single Pulmonary Metastasis of Prostate Cancer: Report of a Rare Case and Literature Review

SYNCHRONOUS DIAGNOSIS OF TESTICULAR AND THYROID CANCER IN A YOUNG MALE

A Proposed Nomogram Model for Recurrence of Non-Muscle Invasive Bladder Carcinoma COMMENT

Metastatic rectal cancer in the ampulla of Vater: A unique case

Radiotherapy and Breast Reconstruction: What Is the Ideal Timing? A Narrative Review

Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden